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Follicle-stimulating hormone receptor (FSHR) is a leucine-rich repeat containing class A 
G-protein coupled receptor belonging to the subfamily of glycoprotein hormone receptors 
(GPHRs), which includes luteinizing hormone/choriogonadotropin receptor (LH/CGR) and 
thyroid-stimulating hormone receptor. Its cognate ligand, follicle-stimulating hormone 
binds to, and activates FSHR expressed on the surface of granulosa cells of the ovary, 
in females, and Sertoli cells of the testis, in males, to bring about folliculogenesis and 
spermatogenesis, respectively. FSHR contains a large extracellular domain (ECD) con-
sisting of leucine-rich repeats at the N-terminal end and a hinge region at the C-terminus 
that connects the ECD to the membrane spanning transmembrane domain (TMD). The 
TMD consists of seven α-helices that are connected to each other by means of three 
extracellular loops (ELs) and three intracellular loops (ILs) and ends in a short-cytoplasmic 
tail. It is well established that the ECD is the primary hormone binding domain, whereas 
the TMD is the signal transducing domain. However, several studies on the ELs and 
ILs employing site directed mutagenesis, generation of chimeric receptors and in vitro 
characterization of naturally occurring mutations have proven their indispensable role in 
FSHR function. Their role in every phase of the life cycle of the receptor like post transla-
tional modifications, cell surface trafficking, hormone binding, activation of downstream 
signaling, receptor phosphorylation, hormone–receptor internalization, and recycling of 
hormone–receptor complex have been documented. Mutations in the loops causing 
dysregulation of these processes lead to pathophysiological conditions. In other GPHRs 
as well, the loops have been convincingly shown to contribute to various aspects of 
receptor function. This review article attempts to summarize the extensive contributions 
of FSHR loops and C-terminal tail to its function.
Keywords: C-tail, extracellular loops, FSH receptor, intracellular loops, receptor function
introduction
The ability of all organisms to receive external stimuli in the form of light, water, sound, hormones, 
odors, to name a few, is essential to bring about a necessary physiological response. This process is 
mediated through cell surface receptors, mainly the G-protein coupled receptors (GPCRs), which 
form the largest and most diverse class of receptors. GPCRs form a repertoire of about 800 receptors 
and are the largest set of drug targets in the market, thus signifying the importance of their study in 
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greater detail. The GPCR superfamily is composed of five major 
families as defined by phylogenetic analysis: glutamate, rhodopsin, 
adhesion, frizzled/taste2, and secretin, which constitute the GRAFS 
classification system (1). All GPCRs are characterized by a common 
structure consisting of a ligand binding extracellular domain (ECD) 
and a signal transducing transmembrane domain (TMD) consist-
ing of seven alpha helices spanning the membrane. The helices 
are connected to each other by means of three extracellular loops 
(ELs) and three intracellular loops (ILs) and end in a cytoplasmic 
tail. The GRAFS system family members differ in the sizes of their 
ECDs, ranging from 60 to 80 residues for growth hormone releasing 
hormone and calcitonin receptors in Family S, to 280–580 residues 
for metabotropic, glutamate receptors in Family G. Rhodopsin 
Family R, receptor ECD sizes vary considerably, as this is the largest 
family and is subdivided into four groups designated as alpha, beta, 
gamma, and delta (2). The delta group consists of the glycoprotein 
hormone receptors (GPHRs), namely, the follicle-stimulating hor-
mone receptor (FSHR), luteinizing hormone/choriogonadotropin 
receptor (LH/CGR), and thyroid-stimulating hormone receptor 
(TSHR). A hallmark of GPHRs is the presence of a large ECD of 
nearly 350–400 residues containing leucine-rich repeats (LRRs), 
which mediate ligand binding with high affinity and specificity 
(3). Several other receptors also harbor the horseshoe-shaped LRR 
structure, which facilitates high-affinity ligand binding, e.g., LGR 
4–7 (4) and some members of the relaxin family peptide recep-
tors, namely RXFP1 and RXFP2 (5). Figure 1 is a diagrammatic 
representation of the GPCR families showing the delta group of 
Rhodopsin family containing leucine-rich repeat GPCRs.
The glycoprotein hormones include the gonadotropins, 
follicle-stimulating hormone (FSH), luteinizing hormone (LH), 
the placental hormone chorionic gonadotropin (CG), and the 
non-gonadotropin thyroid- stimulating hormone (TSH). They 
belong to the cystine-knot growth factor superfamily and share a 
common heterodimeric structure composed of two non-covalently 
associated α and β subunits (6). The α subunits are common for all 
the hormones, whereas the β subunits confer functional specificity. 
All the glycoprotein hormones bind to their cognate GPHRs to 
elicit specific biological effects. FSH binds to FSHR expressed on 
the granulosa cells of the ovary in females, to bring about follicular 
maturation (7) and on the Sertoli cells of the testis in males, where 
it maintains the Sertoli cell population and sperm production (8).
Although a lot of research has been focused on the ECD and 
TMD of FSHR, emerging evidence suggests the importance of the 
ELs and ILs of the receptor in its function. In spite of this, a com-
pendium of available data on the role of the loops and especially 
the ELs of FSHR is lacking. Hence, in this review article, we have 
discussed the involvement of the loops in many FSHR functions 
like cell surface trafficking, hormone binding, signal transduction, 
internalization, and recycling of the hormone–receptor complex. 
A few relevant examples from studies on the loops of LH/CGR 
and TSHR have also been cited.
Life Cycle of FSH Receptor
The life cycle of the FSH receptor, like all other GPCRs, includes 
post translational modifications like glycosylation, palmitoylation, 
and also formation of higher order oligomers in the ER and Golgi 
networks, after which the mature receptor is trafficked to the cell 
surface (9). Abell et al. (10) have shown that deletion mutants 
of ELs of LH/CGR result in the mutant receptor being trapped 
intracellularly showing the importance of ELs in cell surface recep-
tor trafficking. In the case of the FSHR, once the mature receptor 
is localized on the surface of target cells, FSH first binds to the 
high-affinity leucine-rich LRR domains of FSHR, which results 
in additional interactions at the hormone–receptor interface and 
formation of a sulfated Tyr pocket into which the FSHR sulfated 
Tyr335 is inserted, eventually resulting in receptor activation (11). 
This interaction of the ligand with the ECD and relay of the signal 
to the TMD is probably mediated by the ELs of the FSHR. Ji 
et al. (12) carried out an elegant study wherein FSHR mutants, 
which were either binding deficient or signaling deficient, were 
co-expressed. It was seen that FSHR ECD (of signaling deficient 
mutant which was capable of binding FSH) could transactivate 
non-binding FSHR mutants to bring about cAMP or IP produc-
tion but not both. This hormone bound to the ECD probably 
contacts the ELs of the receptor to bring about its activation. In 
TSHR, co-operative signal amplification of constitutively activat-
ing mutations (CAMs) in ELs was shown by Kleinau et al. (13) 
by combining the CAMs and studying the effects in vitro. This 
proved that switching of the receptor from an inactive to an active 
conformation takes place by means of several contacts involving 
both the ECD and the ELs and this is the case for FSHR too. 
Binding of FSH to FSHR triggers several downstream signaling 
pathways other than the canonical cAMP/PKA pathway, such as 
the protein kinase B (PKB/Akt) and serum and glucocorticoid-
induced kinase (Sgk) (14), p38 MAPK (15), ERK1/2 (MAPK3/1) 
(16), and IP3 production (17). The receptor is then uncoupled 
from the G-protein, the desensitized hormone–receptor complex 
becomes internalized, following which most of the complex is 
recycled back to the cell surface and a small fraction is routed to 
lysosomes for degradation (18). Reports from naturally occurring 
and induced mutations of residues in the ELs and ILs of FSHR 
provide evidence for the roles of each loop in various aspects of 
receptor function (Figure 2).
extracellular Loop 1
Alanine scanning mutagenesis of the first five amino acids in 
extracellular loop 1 (EL1) of FSHR showed that a His407Ala 
mutation decreased FSH binding affinity, whereas substitutions 
at Asp405, Thr408, and Lys409 abolished cAMP production (19). The 
revertant mutants showed FSH binding and cAMP production 
similar to WT indicating the importance of EL1 residues in 
FSH binding and signaling. Casas-González et al. (20) reported 
a novel activating FSHR mutation N431I in EL1 in a male who 
exhibited normal spermatogenesis but low-serum FSH levels. 
The mutation impaired the desensitization and internalization 
of the hormone–receptor complex due to its inability to recruit 
beta arrestin proteins, which mediate internalization, as well as 
affected the recycling of the complex, as studied by pulse chase 
assays. In case of TSHR, several activating mutations have been 
identified. One such mutation in the ECD that has been studied 
in detail is S281T/I/N (21). Ala substitution mutagenesis studies 
on the aromatic residues in the vicinity of S281, proximal to TSHR 
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EL1, revealed that mutation of Y481in EL1 along with the surround-
ing aromatic residues was shown to affect receptor signaling. 
Antipeptide antibodies corresponding to EL1 region (residues 
405–426) of FSHR could detect the receptor as determined by flow 
cytometry as well as inhibit FSH binding and cAMP production 
in a dose-dependant manner (22). Thus, FSHR EL1 residues are 
probable secondary hormone binding sites and important in 
FSH binding, cAMP signaling, internalization, and recycling of 
hormone–receptor complex.
extracellular Loop 2
As in most other GPCRs, extracellular loop 2 (EL2) plays an 
indispensable role in FSHR function. Chimeric receptors of FSHR 
ECD/TMD and C-tail of the Drosophila melanogaster fly recep-
tor LGR2 had high-basal cAMP levels suggesting constitutive 
activation of receptor due to removal of the constraint imposed 
by the interaction of exoloops with the ECD (23). In the case 
of the LHR, this constraint was imposed by EL2, and hence, 
it is possibly true for EL2 of the FSHR too. Meduri et al. (24) 
reported a novel homozygous mutation Pro519Thr in a patient 
with primary amenorrhea. The mutation at this highly conserved 
Proline residue resulted in the inability of the mutant receptor 
to traffick to the cell surface and subsequently abolished FSH 
binding and cAMP production. Since the receptor was trapped 
intracellularly, follicular maturation was blocked, resulting in the 
clinical manifestation of premature ovarian failure. Functional 
characterization of a novel heterozygous mutation M512I in a 
woman with spontaneous ovarian hyperstimulation syndrome 
(sOHSS): ovarian enlargement due to several luteinized cysts 
within the ovaries due to abnormally high levels of hCG in 
pregnancy (25) or sometimes due to high levels of TSH (26) 
revealed that the mutation impaired cAMP signaling and PI3K/
AKT pathways (27). Recently, a novel mutation Val514Ala was 
FiGURe 1 | Flowchart showing the classification of GPCR families. The 
rhodopsin family consists of four main groups designated as alpha (α), beta (β), 
gamma (γ), and delta (δ). Members of the delta group include the Leucine-rich 
repeat GPCRs comprising of the three glycoprotein hormone receptors (GPHRs: 
FSHR, LH/CGR, and TSHR), Relaxin/insulin-like family peptide receptors RXFP 
(1–4) and Leucine-rich repeat containing G-protein coupled receptors (LGRs 4–7).
identified in a patient undergoing IVF who exhibited symptoms 
of iatrogenic ovarian hyperstimulation syndrome (aOHSS): 
excessive follicular recruitment and enlargement due to ovarian 
stimulation with exogenous FSH during ART (28). The mutation 
at this conserved Val residue conferred higher cell surface recep-
tor expression, higher FSH binding, and attained saturation of 
cAMP production at low doses of FSH as compared to wild type 
receptor (29). Both the Pro519 and Val514 residues, mentioned here, 
are not only conserved across FSHR of all species but also across 
LHR and TSHR, indicating their importance. The significance of 
FSHR specific, that is, non-conserved residues of EL2 of FSHR was 
demonstrated by swapping six FSHR specific residues in EL2 with 
those from LH/CGR (30). The chimeric EL2M receptor had an 
impaired cAMP response as well as reduced internalization of the 
FSH–FSHR complex. Further, characterization of six individual 
substitution mutants of the FSHR specific residues of EL2 was 
performed and it was found that a L501F mutant showed weak 
interaction with beta arrestins consistent with its low internaliza-
tion, impaired FSH-induced cAMP response, as well as low levels 
of ERK phosphorylation (31). The I505V substitution also affected 
receptor function to some extent. Figure 3 shows the low levels of 
ERK phosphorylation in chimeric EL2M and the point mutants 
L501F and I505V as compared to WT FSHR as reported in Banerjee 
et al. (31). Molecular modeling studies revealed that the L501F and 
I505V substitutions in EL2 resulted in gain of interactions in the 
mutant receptors as compared to wild type receptor (Figure 4). 
Mutations in EL2 of LHR have also been reported to either 
enhance internalization and cAMP signaling (F515A and T521A) or 
impair internalization (S512A and V519A) and cAMP signaling (32) 
indicating the importance of ELs of GPHRs in agonist-induced 
internalization of the hormone–receptor complex. Thus, FSHR 
EL2 residues are essential for cell surface receptor trafficking, FSH 
binding, cAMP/ERK pathway/PI3K pathway, internalization of 
FSH–FSHR complex, and beta arrestin recruitment.
FiGURe 2 | Partial sequence of the human FSHR showing the TMD. The 
seven alpha helices, shown as cylinders designated, I–VII, are connected by 
means of three ELs and three ILs and ends in a short C-tail. Shaded residues 
(●) are naturally occurring mutations, (◾) indicates residues crucial for cell 
surface receptor trafficking, (★) indicates residues important for FSH binding, 
(▴) indicates residues important for FSH-induced cAMP production, (#) 
indicates residues crucial for internalization of FSH-FSHR complex, and (●) 
indicates SNP. Explanation for each of these residues is provided in the text 
wherever applicable. The numbering system followed is according to that for 
the mature receptor without the 17 amino acid residue signal peptide. The 
numbers in parentheses correspond to the amino acid residue number 
including the signal peptide. The ECD comprising residues 1–349 is not shown.
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extracellular Loop 3
Extracellular loop 3 (EL3) is the shortest EL of FSHR consisting 
of only 11 amino acid residues compared to 22 for EL1 and 20 
for EL2. In  vitro characterization of a mutated FSH receptor 
in a compound heterozygous patient (Asp224Val in ECD and 
Leu601Val in EL3), with POF was carried out by Touraine et al. 
(33). Although the cell surface FSHR expression and FSH binding 
affinity of Leu601Val mutant were similar to wild type receptor, 
this substitution impaired cAMP response, which might have 
led to a block in follicular maturation beyond the early antral 
stage. Contrary to this observation, Ryu et  al. (34) and Sohn 
et al. (35) showed that substitution/deletion of Leu583 [same as 
Leu601 reported by Touraine et  al. (33)] and Ile584with a panel 
of amino acids enhanced FSH binding. However, substitutions 
at Leu583, Ile584, and Lys590 abolished cAMP, consistent with the 
study carried out by Touraine et al. (33), thus clearly indicating 
the importance of EL3 residues in cAMP signal transduction. 
Sohn et al. (35) also showed that substitution at Leu583with the 
aromatic amino acids Phe or Tyr, improved the hormone bind-
ing and cAMP induction, but impaired inositol phosphate (IP) 
production. IP induction was also found to be abolished for Ile584 
and Lys590 substitutions. Photoaffinity labeling studies revealed 
that interaction of FSH–FSHR takes place through contact of FSH 
beta with the N-terminal ECD, whereas the FSH alpha subunit is 
oriented toward EL3, indicating the important role of this loop in 
hormone–receptor interaction (36). Along with EL1, antipeptide 
antibodies corresponding to EL3 (FSHR residues 581–591) were 
also found to be surface accessible and capable of inhibiting 
hormone–receptor interaction as determined by radioreceptor 
assay and cAMP assay (22). This information along with the data 
obtained by the study conducted by Sohn et al. (36) indicate that 
the ELs of FSHR probably serve as secondary hormone binding 
sites by means of their interaction with the alpha subunit of FSH. 
In the TSHR, Claus et al. (37) showed that a hydrophobic cluster 
in the center of EL3 is essential for cAMP signaling as seen by 
the loss of signal generation after mutation of residues 652–656, 
comprising the cluster. Another interesting observation with 
respect to the role of EL3 in receptor function was obtained by 
generation of FSHR/LH-CGR chimeric receptors, as mentioned 
earlier (30). Substitution of the three FSHR specific residues in 
EL3 of FSHR with the corresponding residues in LH/CGR resulted 
in the chimeric EL3M receptor exhibiting higher internalization 
of FSH–FSHR complex without any change in the affinity for 
hormone binding. The cAMP signaling response, however, was 
comparable to that of wild type receptor. Pulse chase experiments 
revealed that recycling of the chimeric EL3M receptor was affected. 
Thus, FSHR EL3 residues seem to be essential for FSH–FSHR 
FiGURe 3 | FSH-induced eRK phosphorylation in wild type (wT) FSHR, 
chimeric eL2M FSHR, and the point mutants L501F and i505v (31). 
(A) Representative western blot showing the levels of phospho ERK (P-ERK) 
and total ERK2 in cell lysates from HEK293 cells transiently expressing the 
FSHR constructs and stimulated without or with 100 ng FSH for 5 or 30 min. 
Untransfected cells served as a negative control. (B) Densitometric analysis 
showing the ratio of phosphorylated ERK: total ERK2. The maximum response 
obtained by WT FSHR at 5 min post stimulation with 100 ng FSH was 
considered to be 100% and the % response obtained for the mutants at 0, 5, 
and 30 min post FSH induction (100 ng) was determined by comparing it with 
the maximum response and plotted. The value of *P < 0.05 and ***P < 0.001 
with respect to WT FSHR was considered to be statistically significant.
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interaction, FSH binding, FSH-induced cAMP and IP production 
and internalization, and recycling of FSH–FSHR complex.
intracellular Loop 1
Phosphorylation of FSH receptor post ligand stimulation was 
reported by Quintana et al. (17). Phosphorylation is mediated by 
G-protein-related kinases (GRKs), mainly GRK2 and GRK6, in 
the case of FSHR (38). The phosphorylated receptor then recruits 
adaptor proteins called beta arrestins, which help in mediating the 
internalization of the hormone–receptor complexes via clathrin 
coated pits (39). Generation of a mutant rFSHR-1L where the S/T 
residues in intracellular loop 1 (IL1) of rat FSHR were mutated 
(T369I, S371I, T376N of IL1) greatly affected the phosphorylation of 
the receptor even though FSH binding affinity was unaffected and 
basal cAMP response of mutant receptor was higher (constitutively 
active) (40). This study showed that phosphorylation of IL1 of 
FSHR is required both for uncoupling of receptor in response to 
FSH stimulation and its internalization. Further, abolishing the 
phosphorylation sites at IL1 was shown to affect beta arrestin-2 
recruitment, hence receptor internalization (41). Nechamen et al. 
(42) have also shown interaction of the APPL1 (adaptor protein 
containing PH domain, PTB domain, and leucine zipper motif) 
with hFSHR IL1 and that it links the FSH-stimulated receptor to 
the PI3K/Akt pathway essential for survival of the dominant fol-
licle. Alanine scanning mutagenesis of IL-1 residues demonstrated 
that L377A and F382A mutants showed low-FSH binding, whereas 
K376A showed FSH binding and cAMP production similar to wild 
type FSHR (43). However, the K376A mutation in FSHR inhibited its 
interaction with the adaptor protein APPL1 and abrogation of this 
interaction blocked FSHR-mediated inositol 1, 4, 5-trisphosphate 
(IP3) induction and FSH-induced calcium signaling. Thus, FSHR 
IL1 residues seem to be crucial for FSH binding, FSH-induced 
PI3K pathway, interaction with APPL1 protein to bring about IP3 
production, receptor phosphorylation, and interaction with beta 
arrestins to mediate internalization.
intracellular Loop 2
A yeast-based interaction trap assay identified the interaction of 
intracellular loop 2 (IL2) of FSHR with 14-3-3 tau protein, which is 
important for ER localization of membrane proteins (44). Scanning 
alanine mutagenesis of the IL2 residues 447TLE449 and 450RWH452 
resulted in loss of this interaction with 14-3-3 tau protein thus 
identifying the residues crucial for this interaction (45). Despite 
normal FSH binding, the H452A mutant showed low levels of inter-
nalization and no cAMP production indicating the importance of 
IL2 residues. IL2 of FSHR bears the highly conserved class A GPCR 
ERW motif, which is crucial for receptor activation (46). Timossi 
et al. (47) generated minigene constructs of three ILs of human 
FSHR and found the IL2 to be essential for Gs coupling and cAMP 
production. Minigene encoding free IL-2 as well as minigene IL2 
mutants R467A and R467K and co-expression of full length WT with 
minigene mutant L477A lowered FSH stimulated but not basal 
cAMP levels. Further full length IL2 mutants were made and it 
was found that FSH binding to these mutants was moderately 
affected in the constitutively active mutants L477A/D/P and to a 
lesser extent in L477K/R mutants. Full length FSHR IL2 mutants 
FiGURe 4 | Structural models of the TMD and eLs of wT FSHR, 
chimeric eL2M FSHR, and the point mutants L501F and i505v (31). The 
acquired interactions in chimeric EL2M FSHR and point mutants L501F 
and I505V with the adjacent residues in EL1 and EL3, which are absent in 
WT FSHR is depicted. EL2 region in all the models is shown in yellow. 
The residues involved in interaction in all the four models are circled in 
cyan (Y415, L501/F501, and M503). Residues showing similar interaction in 
chimeric EL2M and L501F mutant are shown in white square boxes (I417 and 
I505/V505). Residues showing similar interaction in chimeric EL2M and I505V 
are shown in green square boxes (Y494 and V582). Hydrogen bonds and 
hydrophobic interactions are depicted in pink and green lines. The models 
were built using Discovery Studio 3.5 and minimized using Schrodinger 
2013 OPLS 2005 force field with default parameters, as described in 
Banerjee et al. (31).
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R467A/H, T470A abolished FSH-induced cAMP production without 
altering basal levels, L477A/D/P mutations led to elevated basal 
cAMP levels, L477K/R mutants showed less FSH-induced cAMP 
production. The FSHR-2L mutant, in which the two threonine of 
IL2 were subjected to alanine substitution (Thr451Ala, Thr453Val), 
and a rFSHR-(2L + 3L) mutant, in which the two threonines in the 
second IL along with the seven Ser/Thr residues in the intracellular 
loop 3 (IL3) were substituted with alanine residues (Thr451Ala, 
Thr453Val, Thr536Ala, Thr541Ala, Ser544Ala, Ser545Ala, Ser546Ala, 
Ser547Ala, Thr549Ala), were deficient in phosphorylation, bound 
FSH with comparable affinity to WT but showed low levels of 
FSH-induced cAMP production (inactivating mutations) (48). 
Further, in this study, it was shown that rFSHR-D389N and rFSHR-
Y530F (D and Y are highly conserved residues across GPCRs), two 
inactivating mutations possessing intact phosphorylation sites 
showed impairment in phosphorylation. Overexpression with 
GRK-2 was shown to rescue phosphorylation of both the mutants 
but internalization of only D389N mutant, whereas overexpression 
of arrestin-3 (β-arrestin 2) could rescue internalization of both 
mutants providing the first evidence of the role of beta arrestins in 
FSH-mediated receptor internalization post receptor phosphoryla-
tion with GRKs. In LHR too, mutagenesis studies revealed several 
residues in IL2, like Lys455 and His460, to be essential for ligand 
binding and Glu441and His460 to be important for cAMP response 
(49). Thus, FSHR IL2 residues are especially important for cAMP 
production and also for receptor phosphorylation.
intracellular Loop 3
A synthetic peptide corresponding to residues 533–555 of IL3 
of the rat FSHR was shown to inhibit cAMP production and 
estradiol synthesis in cultured Sertoli cells from immature rat 
testes (50). Along with IL1, mutations in IL3 residues also were 
shown to affect receptor phosphorylation; however, the effect was 
not as pronounced as in IL1 mutation. The rFSHR-3L mutant, 
in which the Ser/Thr residues in IL3 were mutated to alanine 
(Thr536Ala, Thr541Ala, Ser544Ala, Ser545Ala, Ser546Ala, Ser547Ala, 
Thr549Ala of IL3)and a rFSHR-(3L + CT) mutant, in which the 
Ser/Thr residues in both IL3 and C-tail were mutated to alanine 
(Thr536Ala, Thr541Ala, Ser544Ala, Ser545Ala, Ser546Ala, Ser547Ala, 
Thr549Ala, Ser624Ala), showed unaltered FSH binding, whereas 
rFSHR-3L was found to be a constitutively active mutant, as it 
exhibited high-basal cAMP response (40). The mutant receptors 
affected the phosphorylation of FSHR to some extent, as well as 
its uncoupling from adenylyl cyclase enzyme without affecting 
its internalization. Using chimeric FSHR and LHR receptors, the 
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interaction of threonine residues in IL3 with beta arrestin proteins, 
and hence, internalization of these gonadotropin receptors was 
shown by Bhaskaran et al. (51). GPCRs harbor a BBXXB motif 
(where B represents a basic amino acid whereas any amino acid 
can be presented at “X”) in the intracellular domains, which is 
an essential determinant of receptor activation. FSHR contains a 
reverse BXXBB situated at the juxtamembrane region of IL3and C 
tail, which was subjected to Ala substitution mutagenesis (52). All 
the IL3 mutant receptors BXXAB, AXXBB, and BXXBA showed 
FSH binding similar to WT, but binding was affected in the same 
three mutants of C-tail. However, cAMP production was abolished 
in AXXBB and BXXBA mutants but was normal in BXXAB mutant 
of IL3. In the case of the C-tail, cAMP production of all three 
mutants was affected. Thus, it appears that the BXXBB motif at 
the IL3 of the hFSHR is essential for Gαs coupling and cAMP 
production, whereas the same motif in the C-tail is more important 
for membrane expression as the mutation resulted in an immature 
form of the receptor, which was unable to bind the hormone. An 
interesting study by Cohen et al. (53) identified IL3 to be a site 
of FSHR ubiquitination by a yeast two-hybrid screen. However, 
mutating the only Lys residue available for ubiquitination (K555R) 
did not disrupt FSHR–ubiquitin interaction indicating that other 
determinations of receptor ubiquitination exist. The importance 
of this loop is further emphasized by the presence of naturally 
occurring mutations in the loop that affect receptor function. Beau 
et al. (54) reported that a woman with secondary amenorrhea and 
high-serum FSH levels was found to harbor two FSHR mutations: 
Ile160Thr (ECD) and Arg573Cys (IL3). The mutation in the ECD 
affected cell surface receptor expression, whereas the IL3 mutation 
impaired cAMP signaling. A constitutively active mutation D567G 
was identified by Gromoll et al. (55) in a hypophysectomized man. 
Later in 2003, Smits et al. (56) reported a mutation at the same posi-
tion in FSHR IL3 in a woman with spontaneous OHSS. The D567N 
substitution in this case conferred high-basal cAMP response as 
well as loss of functional specificity as the mutant receptor showed 
a dose-dependent increase in cAMP production upon hCG or 
TSH stimulation. The importance of this residue is further cor-
roborated by the fact that it lies in a protein kinase CK2 consensus 
site and brings about phosphorylation of adaptor proteins like beta 
arrestins, which mediate receptor internalization (57) via their 
interaction with FSHR (58). Kluetzman et al. (59) showed that 
both the naturally occurring D550G (same as D567G) mutation and 
the alanine substituted mutation D550A showed accumulation of 
FSH in mutant receptors in intracellular stores due to decreased 
degradation after internalization as evidenced by radioreceptor 
assay as well as visualization by confocal microscopy. Thus, FSHR 
IL3 residues seem to be important for receptor phosphorylation, 
cAMP response as well as ubiquitination.
C-Terminal Tail
As in all other GPCRs, the carboxy-terminal tail bears the highly 
conserved F(X)6LLmotif (where X can be any residue, and L is 
leucine or isoleucine), which is important for trafficking of the 
mature receptor from ER to the cell surface (60). This motif is 
located between 616 and 624 residues in the mature FSH receptor 
(9). Another important post translational modification in GPHRs 
is palmitoylation of the cysteine residues and this is crucial for 
receptor endocytosis and other post endocytic events (61). Two 
conserved cysteine residues (at positions 629 and 655) and one 
non-conserved Cys residue (at position 627) are present in the 
C-tail of human FSHR, which are potential sites for S-acylation 
with palmitic acid, were investigated by Uribe et al. (62). Low-FSH 
binding in C629A, double mutants C627/629A and C629/655A, and the 
triple C627/629/655A receptor mutants without change in FSH binding 
affinity was observed due to low-cell surface FSHR expression of 
mutants, whereas low internalization for FSH–FSHR complex of 
Cys655A/S/T mutants was seen. C629A, C655A/S/T, the double mutant 
C627/629A, and the triple mutant C627/629/655A showed low-cAMP pro-
duction. The triple mutant C627/629/655A did not show palmitoylation 
indicating the importance of all the three residues for palmitoyla-
tion. Single-alanine substitutions of residues in the IL3 of TSHR 
also revealed that the residues were crucial for G-protein activation 
(63). Truncation mutants of the C-terminal tail (removal of the 
last eight residues) of hFSHR and rFSHR decreased the amount of 
internalized 125I-hFSH (18). Confocal microscopy analysis showed 
that in contrast to the internalized WT receptors, which localized 
only to endosomes, the internalized truncated receptors localized 
to both endosomes and lysosomes. This study showed that most of 
the FSH–FHSR complex gets recycled back to the cell surface and 
truncation of eight residues from the C-tail reroute a substantial 
portion of the internalized FSH–FSHR complex to a degradation 
pathway. Ala substitution of the Ser/Thr cluster T638A, T640A, S641A, 
S642A, T644A in the C-tail of rFSHR showed similar FSH binding 
affinity to mutant receptor as compared to WT but impaired 
internalization of FSH–FSHR complex (64). Loss of the Ser/Thr 
cluster in the mutant FSHR resulted in enhanced cAMP production 
due to its inability to get desensitized, impaired phosphorylation, 
β-arrestin recruitment, and hence, impaired internalization of 
FSH–FSHR substantiated the importance of the C-tail in FSHR 
function. Thomas et al. (65) reported that FSHR forms oligomers 
in a constitutive manner before coming to the cell surface and dis-
covered during the course of this study that the C-terminal epitope 
tags undergo proteolytic processing, so such C-terminal tagged 
receptors could not be exploited to study receptor oligomerization. 
To overcome this shortcoming, Mazurkiewicz et al. (66) generated 
chimeras of FSHR and extreme C-tail fluorescent fusion proteins: 
FSHR-LHRcT-YFP/FSHR-LHRcT-mCherry pairs possessing 
amino acid residues 1–611 of the hFSHR and residues 604–674 
of the rLHR. Fluorescence correlation spectroscopy and photon 
counting histogram studies with these chimeric FRET pairs dem-
onstrated the presence of freely diffusing FSHR homodimers on the 
surface of live cells. FRET experiments also demonstrated that the 
hFSHR-rLHR-cT chimera formed hetero-dimers/hetero-oligomers 
with LHR and this possibly occurred during granulosa cell dif-
ferentiation. Zariñán et al. (67) had reported that co-transfection 
of WT FSHR with mutants R556A (IL3) or R618A (C-tail) showed 
dose-dependent inhibition in FSH binding and cAMP produc-
tion with increasing amounts of mutant DNA and subsequently 
rescue of function by co-transfection with WT fragments of TMD 
5, 6, or 7 and/or C-tail suggesting oligomerization of FSHR. The 
crucial role played by the C-tail in receptor function is reinforced 
by the existence of a SNP p.Asn680Ser (rs6166), which has been 
studied extensively in various ethnic groups across the world and is 
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believed to serve as a marker to predict ovarian response in women 
undergoing assisted reproductive technology programs (68–74). 
Thus, the C-tail of FSHR plays an indispensable role in palmitoyla-
tion, cell surface receptor trafficking, receptor phosphorylation, 
interaction with beta arrestin proteins, and hence, internalization 
of FSH–FSHR complex.
Conclusion and Future Directions
Genetic alterations in GPCRs, resulting in loss or gain of function, 
lead to several pathological conditions and are being studied by 
several groups to develop drugs targeted at the receptor to rescue its 
function (75, 76). Knowledge of combination of SNPs in FSH beta 
and FSHR is essential for determining patient risk/treatment out-
come and for designing treatment in cases of infertility (77). Also, 
in vitro studies on several naturally occurring mutations [reviewed 
by Desai et al. (78)] and studies on both FSH beta and FSHR knock-
out mice (79) indicate the pivotal role of this  hormone–receptor 
interaction, failure of which leads to reproductive dysfunctions. 
Owing to the large size of the receptor, its interaction with FSH takes 
place at several discrete regions on the ECD and this hormone–
receptor ECD complex possibly makes contacts with the ELs and 
the signal is then relayed downstream through the TMD. Other than 
mutations in the ECD and TMD, which may result in intracellular 
retention of the receptor, its inability to bind FSH or bring about 
signal transduction, several such mutations in the loops display 
similar characteristics and this necessitates their study in greater 
detail. Therefore, in order to develop drugs targeted to rescue the 
function of the receptor, a thorough understanding of the epitopes 
crucial for FSH–FSHR interaction is a must. In recent times, several 
small molecule FSHR agonists, which can be orally administered 
like Org 214444-0 (80), FSHR allosteric modulators like Compound 
5 (81) have been developed, which can be administered to patients 
for ovulation induction. Pharmacoperones (pharmacological chap-
erones that assist in folding and routing of mutant receptors to the 
cell surface) like Org 41841 have been shown to rescue the function 
of the A189V FSHR mutant, which was trapped intracellularly and 
hence exhibited low-cell surface FSHR expression (82). As these 
molecules hold great therapeutic potential, the understanding of the 
biochemical mechanism of their interaction with the receptor and 
identification of sites of interaction with the receptor is imperative. 
Along with the ECD and TMD, detailed analysis of the residues 
in the ELs and ILs is therefore of utmost importance given their 
versatile roles in FSH–FSHR interaction.
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